Defining clinically meaningful benefit in mild-to-moderate hidradenitis suppurativa trials.
Islam RK, Falgout LM, Culotta NJ, Sayed CJ, Haas CJ
Journal of the American Academy of DermatologyIn the feed 21 Aug 2026, published online 21 Aug 2026, issue 2026 Aug 21, added to PubMed 21 Aug 2026
Topics: Hidradenitis suppurativaJAK inhibitors & other targeted pills
Abstract
PubMed has no abstract for this paper, as is usual for research letters, correspondence and editorials. The publisher’s page has the full paper.
PMID 42628802 · DOI 10.1016/j.jaad.2026.06.153